{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Lumry, W. R., A. J. Castaldo, M. K. Vernon, M. B. Blaustein, D. A. Wilson and P. T. Horn', '(2010). \"The humanistic burden of hereditary angioedema: Impact on health-related quality', 'of life, productivity, and depression.\" Allergy Asthma Proc 31(5): 407-414.', 'Maurer, M., M. Magerl, I. Ansotegui, E. Aygoren-Pursun S. Betschel, K. Bork, T. Bowen,', 'H. Balle Boysen, H. Farkas, A. S. Grumach, M. Hide, C. Katelaris, R. Lockey, H. Longhurst,', 'W. R. Lumry, I. Martinez-Saguer, D. Moldovan, A. Nast, R. Pawankar, P. Potter, M. Riedl,', 'B. Ritchie, L. Rosenwasser, M. Sanchez-Borges, Y. Zhi, B. Zuraw and T. Craig (2018). \"The', 'international WAO/EAACI guideline for the management of hereditary angioedema-The', '2017 revision and update.\" Allergy 73(8): 1575-1596.', 'Ohsawa, I., D. Honda, S. Nagamachi, A. Hisada, M. Shimamoto, H. Inoshita, S. Mano and', 'Y. Tomino (2015). \"Clinical manifestations, diagnosis, and treatment of hereditary', 'angioedema: survey data from 94 physicians in Japan.\" Ann Allergy Asthma Immunol', '114(6):492-498.', 'Saxena, P., P. Thompson, Y. d\\'Udekem and I. E. Konstantinov (2011). \"Kallikrein-kinin', 'system: a surgical perspective in post-aprotinin era.\" J Surg Res 167(1): 70-77.', 'Weller, K., M. Magerl, A. Peveling-Oberhag, P. Martus, P. Staubach and M. Maurer (2016).', '\"The Angioedema Quality of Life Questionnaire (AE-QoL) - assessment of sensitivity to', 'change and minimal clinically important difference.\" Allergy 71(8): 1203-1209.', 'Yamamoto, T., T. Horiuchi, H. Miyahara, S. Yoshizawa, J. Maehara, E. Shono, K.', 'Takamura, H. Machida, K. Tsujioka, T. Kaneko, N. Uemura, K. Suzawa, N. Inagaki, N.', 'Umegaki, Y. Kasamatsu, A. Hara, Y. Arinobu, Y. Inoue, H. Niiro, Y. Kashiwagai, S.', 'Harashima, T. Tahira, H. Tsukamoto and K. Akashi (2012). \"Hereditary angioedema in', 'Japan: genetic analysis of 13 unrelated cases.\" Am J Med Sci 343(3): 210-214.', 'Zuraw, B. L., A. Banerji, J. A. Bernstein, P. J. Busse, S. C. Christiansen, M. Davis-Lorton,', 'M. M. Frank, H. H. Li, W. R. Lumry and M. Riedl, US Hereditary Angioedema Association', 'Medical Advisory Board (2013). \"US Hereditary Angioedema Association Medical Advisory', 'Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1', 'Inhibitor Deficiency.\" J Allergy Clin Immunol Pract 1(5): 458-467.', 'Zuraw, B. L. and S. C. Christiansen (2011). \"Pathophysiology of hereditary angioedema.\"', 'Am J Rhinol Allergy 25(6): 373-378.', '107']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '16.', 'APPENDICES', '16.1.', 'DMID Adult Adverse Event Table (DRAFT, Publish Date:', 'November 2007)', 'For the purposes of this protocol, the title of the Division of Microbiology and Infectious Disease', \"(DMID) table to be used grade adverse events is referred to as the 'DMID Adult Adverse Event\", \"Table. The criteria contained in the 'DMID Adult Adverse Event Table' has been unaltered\", \"from the published DMID table under the name 'DMID Adult Toxicity Table (DRAFT, Publish\", 'Date: November 2007).', 'Copies of the DMID Adult Adverse Event Table will be available to the medical staff throughout', 'the project.', '108']\n\n###\n\n", "completion": "END"}